Tau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau
We measured tau extent, magnitude, and a new combination of these metrics, Tau-MaX. Extent increases early in disease, while magnitude increases in later disease stages. Tau-MaX captures this shift and is closely associated with phosphorylated tau217 and cognition. Global Tau-MaX performed similarly to or better than meta-region of interest tau magnitude or extent. Tau-MaX provides a region-agnostic measure of tau burden to track progression.
Authors
- Ilya M. Nasrallah (ORCID: https://orcid.org/0000-0003-2346-7562)
- Katheryn A Q Cousins (ORCID: https://orcid.org/0000-0003-1879-2766)
- Corey T. McMillan (ORCID: https://orcid.org/0000-0002-7581-6405)
- Sandhitsu R. Das (ORCID: https://orcid.org/0000-0003-0530-2887)
- John A. Detre (ORCID: https://orcid.org/0000-0002-8115-6343)
- Paul A. Yushkevich (ORCID: https://orcid.org/0000-0001-8543-4016)
- Edward B. Lee (ORCID: https://orcid.org/0000-0002-4589-1180)
- Thomas F. Tropea
- Christopher Brown (ORCID: https://orcid.org/0000-0003-2057-3976)
- Yi‐Ju Li (ORCID: https://orcid.org/0000-0001-6996-4834)
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1002/alz.70346
- Citations
- 6
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 8.83
Funders
- Alzheimer's Association
- Eli Lilly and Company
- Pennsylvania Department of Health
- Fred A. And Barbara M. Erb Family Foundation
- National Institutes of Health
- Avid Radiopharmaceuticals